NCT01637025已完成不适用
A Prospective, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Traumastem as an Adjunct to Hemostasis for Tissue Bleeding in Open Cardiac, Intra-abdominal (Including Retroperitoneal) and Pelvic Surgery
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 111
- 试验地点
- 24
- 主要终点
- Occurrence of adverse events (AEs)/ adverse device effects (ADEs)
研究概览
简要总结
The purpose of this study is to evaluate the safety and effectiveness of Traumastem to help stop bleeding in participants undergoing open cardiac, intra-abdominal (including retroperitoneal) and pelvic surgery as compared to Surgicel® Original (Surgicel; in some countries marketed as Tabotamp®)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •AT SCREENING:
- •Participants and/or legal representative has/have provided signed informed consent. An assent form should be signed by Participants less than 18 years of age, if possible;
- •Participants undergoing planned (non-emergency) open cardiac, intra-abdominal (including retroperitoneal) and pelvic surgery;
- •Participants of childbearing potential present with a negative serum pregnancy test, and agree to employ adequate birth control measures for the duration of the study. Acceptable contraception methods are restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices or licensed hormonal products;
- •Participants are willing and able to comply with the requirements of the clinical investigation plan (CIP).
- •INCLUSION CRITERIA INTRA-OPERATIVE:
- •Soft tissue, vascular/anastomotic or parenchymal bleeding is present after primary surgical hemostasis has been achieved. The TBS is defined as intra-operative bleeding where conventional methods for achieving hemostasis are ineffective (based on the type of tissue) or impractical (based on the location) and where treatment with topical hemostatic adjuncts such as Traumastem is deemed appropriate for use.
排除标准
- •Emergency surgery;
- •Transplantation surgery;
- •Minimally invasive surgery;
- •Neurological and ophthalmological surgery;
- •Major arterial bleeding at the target bleeding site (TBS);
- •Major intra-operative complications that require resuscitation or deviation from the planned surgical procedure;
- •Severe local inflammation at the operating field;
- •Any prior radiation therapy to the operating field;
- •Known severe congenital or acquired immunodeficiency (eg, human immunodeficiency virus [HIV] infection or long-term [> 3 months] treatment with immunosuppressive drugs);
- •Known hypersensitivity to components of the investigational device;
- •Participant is pregnant or lactating at the time of enrollment or becomes pregnant prior to the planned surgery. If the participant becomes pregnant during the 30 days following treatment exposure, attempts will be made to follow her through completion of the pregnancy. The investigator will record a narrative description of the course of the pregnancy and its outcome;
- •Participant has a clinically significant medical, psychiatric, or cognitive illness, or drug/alcohol abuse that, in the opinion of the investigator, would affect participant's safety or compliance;
- •Participant has participated in another clinical study involving an investigational device/drug within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational device/drug during the course of this study.
研究组 & 干预措施
Traumastem - oxidized cellulose strip
Experimental
干预措施: Oxidized cellulose strip (Device)
Surgicel® Original - oxidized regenerated cellulose strip
Active Comparator
干预措施: Oxidized regenerated cellulose strip (Device)
结局指标
主要结局
Occurrence of adverse events (AEs)/ adverse device effects (ADEs)
时间窗: ≤30 ± 5 days/ end-of-study visit after device application
Occurrence of adverse events (AEs)/ adverse device effects (ADEs) up to 30 ± 5 days/ end-of-study visit after device application.
次要结局
未报告次要终点
研究者
研究点 (24)
Loading locations...
相似试验
已完成
不适用
Prevention and Early Detection of Ulcer Recurrence in Patients With Type II Diabetes MellitusRecurrenceDiabetic FootQuality of LifeThermographyNCT06434922Institute Technology and Health Muhammadiyah West Kalimantan60
已完成
2 期
Prevention Of Recurrence Of Atrial FibrillationFibrillation, AtrialNCT00041496GlaxoSmithKline520
Unknown
4 期
A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIKPresbyopiaMyopiaHyperopiaNCT01977807Technolas Perfect Vision GmbH100
Unknown
4 期
A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and PresbyopiaMyopiaPresbyopiaHyperopiaNCT02112968Technolas Perfect Vision GmbH97
Unknown
4 期
A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIKHyperopiaMyopiaNCT02071576Technolas Perfect Vision GmbH42